Apallergy.2013.3.two.127. 89. O’Hara J, Jones N. ” Post-nasal drip syndrome”: most individuals with purulent nasal secretions usually do not complain of chronic cough. Rhinology. 2006;44(4):270.90. Tatar M, Plevkova J, Brozmanova M, Pecova R, Kollarik M. Mechanisms of your cough connected with rhinosinusitis. Pulm Pharmacol Ther. 2009;22(2):121. doi:10.1016j.pupt.2008.11.014. 91. Pecova R, Vrlik M, Tatar M. Cough sensitivity in allergic rhinitis. J Physiol Pharmacol. 2005;56 Suppl four:171. 92. Plevkova J, Poliacek I, Antosiewicz J, Adamkov M, Jakus J, Svirlochova K, et al. Intranasal TRPV1 agonist capsaicin Methylene blue site challenge and its effect on c-fos expression within the guinea pig brainstem. Respir Physiol Neurobiol. 2010;173(1):11. doi:ten.1016j.resp.2010.05.015. 93. Buday T, Brozmanova M, Biringerova Z, Gavliakova S, Poliacek I, Calkovsky V, et al. Modulation of cough response by 1,2-Dioleoyl-3-trimethylammonium-propane chloride supplier sensory inputs in the nose – role of trigeminal TRPA1 versus TRPM8 channels. Cough. 2012;eight(1):11. doi:10.11861745-9974-8-11. 94. Yancy Jr WS, McCrory DC, Coeytaux RR, Schmit KM, Kemper AR, Goode A, et al. Efficacy and tolerability of treatments for chronic cough: a systematic assessment and meta-analysis. Chest. 2013;144(six):18278. doi:ten.1378chest.13-0490. 95. Morice AH, Menon MS, Mulrennan SA, Everett CF, Wright C, Jackson J, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007;175(four):312. doi:10.1164rccm.200607-892OC. 96. Dickinson R, Morjaria J, Wright C, Morice A. Is opiate action in cough as a result of sedation Ther Adv Chronic Dis. 2014;5(5):200. 97. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583. 98. Faruqi S, Wright C, Thompson R, Morice AH. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthier volunteers. Br J Clin Pharmacol. 2014;78(6):12720. doi:ten.1111bcp.12458. 99. Bem JL, Dextromethorphan PR. An overview of safety difficulties. Drug Saf. 1992;7(three):190. 100. Khalid S, Murdoch R, Newlands A, Wise K, Kelsall A, Holt K, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in sufferers with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134(1):562. doi:ten.1016 j.jaci.2014.01.038. 101. Niimi A. Cough, asthma, and cysteinyl-leukotrienes. Pulm Pharmacol Ther. 2013;26(5):514. doi:10.1016j.pupt.2013.06.003. 102. Spector SL, Tan RA. Effectiveness of montelukast within the treatment of cough variant asthma. Ann Allergy Asthma Immunol. 2004;93(three):232. doi:ten.1016 S1081-1206(10)61493-7. 103. Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of your leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma. 2002;39(four):291. 104. Kita T, Fujimura M, Ogawa H, Nakatsumi Y, Nomura S, Ishiura Y, et al. Antitussive effects on the leukotriene receptor antagonist montelukast in sufferers with cough variant asthma and atopic cough. Allergol Int. 2010;59(2):1852. doi:10.2332allergolint.09-OA0112. 105. Cai C, He MZ, Zhong SQ, Tang Y, Sun BQ, Chen QL, et al. Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis: a pilot study. Respir Med. 2012;106(10):13695. doi:ten.1016 j.rmed.2012.06.009. 106. Chang AB, Winter D, Acworth JP. Leukotriene receptor antagonist for prolonged non-specific cough in young children. Cochrane Database Syst Rev. 2006;two, CD005602. doi:ten.100214651858.CD005602.pub.
